Atossa Therapeutics Secures Patent for Z-Endoxifen, Enhancing Breast Cancer Treatment Strategy

Atossa Therapeutics Strengthens Intellectual Property for Z-Endoxifen

Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company dedicated to advancing breast cancer treatment and prevention, announces a pivotal development in its global intellectual property strategy with the issuance of a key patent in Israel. The patent, designated No. 304863, covers comprehensive methods for making and utilizing Z-endoxifen, a drug with the potential to significantly impact breast cancer therapy. This patent not only reinforces Atossa's lead program but also enhances its competitive position in major markets by providing strong intellectual property protections.

The newly granted patent, which was awarded on July 2, 2025, encompasses oral, delayed-release formulations of Z-endoxifen that contain at least 90% by weight of the drug, while also specifying impurity limits of less than 2%. This is critical as the formulation's characteristics, including dose strengths of 1–4 mg and 8 mg, align with regulatory expectations and enhance therapeutic efficacy. The patent also outlines essential pharmacokinetic performance targets, ensuring that patients receive a consistent and effective treatment. Additionally, Atossa's innovative manufacturing methods, which improve the Z-isomer through advanced crystallization techniques, reflect the company’s commitment to quality-by-design in drug development.

Steven Quay, M.D., Ph.D., Atossa’s Chairman and CEO, highlights the significance of this patent issuance, emphasizing that strong intellectual property is essential for supporting the company’s strategy surrounding Z-endoxifen. By securing this patent and a Certificate of Patent Renewal from the Israel Patent Office, Atossa solidifies its position in the market while aiming to deliver high-quality therapeutic options to patients. The company’s focus on disciplined capital allocation and innovative practices underlines its commitment to addressing the critical unmet needs in breast cancer therapies.

In addition to the patent developments, Atossa Therapeutics continues to prioritize the quality and efficacy of its drug formulations. The patent’s detailed specifications ensure that Z-endoxifen not only meets regulatory standards but also offers potential benefits to patients through enhanced pharmacological performance. As Atossa progresses through its clinical trials, the emphasis on intellectual property protection will play a pivotal role in its operational strategy.

Overall, Atossa's advancements in securing robust patent protections for Z-endoxifen reflect its dedication to innovation in breast cancer treatment. These developments not only bolster the company’s market position but also aim to improve patient outcomes in a field that demands continued research and effective therapies.